Compare ALEMBIC with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs GSK PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC GSK PHARMA ALEMBIC/
GSK PHARMA
 
P/E (TTM) x 59.5 54.2 109.7% View Chart
P/BV x 5.1 12.2 41.9% View Chart
Dividend Yield % 0.2 1.3 15.4%  

Financials

 ALEMBIC   GSK PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
GSK PHARMA
Mar-19
ALEMBIC/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs723,595 2.0%   
Low Rs341,253 2.7%   
Sales per share (Unadj.) Rs4.7184.7 2.5%  
Earnings per share (Unadj.) Rs6.126.3 23.2%  
Cash flow per share (Unadj.) Rs6.229.2 21.4%  
Dividends per share (Unadj.) Rs0.2020.00 1.0%  
Dividend yield (eoy) %0.40.8 45.8%  
Book value per share (Unadj.) Rs40.7126.3 32.2%  
Shares outstanding (eoy) m267.03169.40 157.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.313.1 85.8%   
Avg P/E ratio x8.792.2 9.4%  
P/CF ratio (eoy) x8.583.1 10.2%  
Price / Book Value ratio x1.319.2 6.8%  
Dividend payout %3.376.1 4.3%   
Avg Mkt Cap Rs m14,139410,626 3.4%   
No. of employees `000NA5.0 0.0%   
Total wages/salary Rs m2075,372 3.9%   
Avg. sales/employee Rs ThNM6,306.7-  
Avg. wages/employee Rs ThNM1,083.1-  
Avg. net profit/employee Rs ThNM898.0-  
INCOME DATA
Net Sales Rs m1,25531,281 4.0%  
Other income Rs m3701,023 36.2%   
Total revenues Rs m1,62532,304 5.0%   
Gross profit Rs m1116,009 1.8%  
Depreciation Rs m38486 7.8%   
Interest Rs m26 28.3%   
Profit before tax Rs m4426,540 6.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m242,373 1.0%   
Profit after tax Rs m1,6304,454 36.6%  
Gross profit margin %8.919.2 46.1%  
Effective tax rate %5.436.3 14.9%   
Net profit margin %129.814.2 911.9%  
BALANCE SHEET DATA
Current assets Rs m1,86720,061 9.3%   
Current liabilities Rs m59114,543 4.1%   
Net working cap to sales %101.617.6 576.2%  
Current ratio x3.21.4 228.9%  
Inventory Days Days9457 166.0%  
Debtors Days Days7414 523.0%  
Net fixed assets Rs m1,79114,343 12.5%   
Share capital Rs m5341,694 31.5%   
"Free" reserves Rs m10,32419,704 52.4%   
Net worth Rs m10,85821,398 50.7%   
Long term debt Rs m412 2,060.0%   
Total assets Rs m11,59139,113 29.6%  
Interest coverage x260.91,091.0 23.9%   
Debt to equity ratio x00 4,059.8%  
Sales to assets ratio x0.10.8 13.5%   
Return on assets %14.111.4 123.4%  
Return on equity %15.020.8 72.1%  
Return on capital %15.231.9 47.6%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m19534 3.6%   
Fx outflow Rs m2647,091 3.7%   
Net fx Rs m-244-6,557 3.7%   
CASH FLOW
From Operations Rs m2363,994 5.9%  
From Investments Rs m-224-1,433 15.6%  
From Financial Activity Rs m-27-3,584 0.7%  
Net Cashflow Rs m-15-1,023 1.4%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 2.0%  
FIIs % 9.7 23.8 40.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 15.4 169.5%  
Shareholders   54,701 102,036 53.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   ELDER PHARMA  FDC  NEULAND LABS  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - WYETH COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS